GlassScriptPhysician profile
Donna Zarandi
NPI 1649807587
$1,883.16
in general payments reported to CMS, 2019-2025
21 companies · $955 in 2025
The $955 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.17 · 2023: $84.87 · 2024: $830 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.75 | 2023-2025 | Teflaro |
| Lilly USA, LLC | $190.45 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $190.37 | 2024-2025 | Gardasil 9, Capvaxive, Pifeltro |
| Glaxosmithkline, LLC. | $172.28 | 2024-2025 | Arexvy, Shingrix |
| Cumberland Pharmaceuticals, INC. | $116.03 | 2023-2025 | Vibativ |
| Viiv Healthcare Company | $101.42 | 2025 | Cabenuva, Apretude |
| Novo Nordisk INC | $68.22 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $54.17 | 2024-2025 | Vowst |
| Exact Sciences Corporation | $48.95 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.59 | 2022-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $37.33 | 2025 | Veozah |
| Pfizer INC. | $34.44 | 2024-2025 | |
| Convatec INC. | $26.26 | 2024 | |
| Abiomed | $23.23 | 2025 | |
| Sanofi Pasteur INC. | $19.57 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.60 | 2025 | Evenity |
| Sumitomo Pharma America, INC. | $18.29 | 2025 | Gemtesa |
| Shionogi INC | $17.59 | 2025 | Fetroja |
| Seqirus USA INC | $17.00 | 2024 | Fluad, Flucelvax |
| Napo Pharmaceuticals INC | $17.00 | 2024 | Mytesi |
| Paratek Pharmaceuticals, INC. | $13.62 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Zarandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.